Skip to main content

Table 1 Demographic characteristics of the study participants

From: Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease

  Cohort 1 Cohort 2 Cohort 3
Biomarker-negative controls Biomarker-positive AD Control individuals Biomarker-negative controls Biomarker-positive AD
Sample size 15 18 47 16 19
Age, y 67.3 ± 9.1 77.4 ± 5.8a 45,9 ± 15,2 65.5±15.3 67.7±8.6
Gender, F, n (%) 5/15 (33.3%) 10/18 (55.5%) 27/47 (57.4%) 10/16 (62.5%) 10/19 (52.6%)
CSF Aβ42, pg/ml 1002.0 ± 286.6 450.9 ± 67.9a N/A 877.2 ± 160.7 499.4 ± 87.0a
CSF total-tau, pg/ml 262.0 ± 81.0 773.7 ± 406.9a N/A 209.2 ± 61.2 577.3 ± 136.1a
CSF p-tau181 (Innotest), pg/ml 42.5 ± 12.7 91.2 ± 26.2a N/A 28.4 ± 8.0 88.9 ± 23.7a
CSF p-tau181 (Simoa), pg/ml N/A N/A N/A 176.4 ± 57.3 895.8 ± 350.9a
CSF p-tau231 (Simoa), pg/ml N/A N/A N/A 154.4 ± 49.4 777.9 ± 260.8a
Plasma p-tau231, pg/ml 6.5 ± 3.4 13.4 ± 5.2a N/A N/A N/A
Plasma p-tau181, pg/ml 5.8 ± 2.8 10.4 ± 4.1a 1.1 ± 0.4 N/A N/A
Serum p-tau231, pg/ml 2.5 ± 2.3 6.4 ± 2.7a N/A 1.1 ± 1.1 3.8 ± 4.3a
Serum p-tau181, pg/ml 4.5 ± 2.0 9.3 ± 3.4a 0.6 ± 0.3 2.5 ± 2.2 10.1 ± 10.4a
  1. Biomarker and age differences were tested using Mann-Whitney test
  2. Biomarker concentrations are shown as mean ± standard deviation (SD)
  3. Note that p-tau measurements were performed with different methods in cohorts 1 and 3 (validated in-house assays) vs. cohort 2 (commercial kit from Quanterix)
  4. N/A, not available
  5. aSignificant difference compared with controls